Switching from donepezil to rivastigmine is well tolerated: Results of an open-label safety and tolerability study

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 7, Issue 2, 2005, Pages 43-48

  Sadowsky, Carl H ^a,d   Farlow, Martin R ^b   Atkinson, Leone ^c   Steadman, Jennifer ^c   Koumaras, Barbara ^c   Chen, Michael ^c   Mirski, Dario ^c  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Premiere Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO; RIVASTIGMINE;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; ERUCTATION; FEMALE; FLATULENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; SIDE EFFECT; VOMITING;

EID: 26444560307     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v07n0201     Document Type: Article

References (42)

1. Lamb HM, Goa KL. Rivastigmine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 2001;19:303-318
2. Evans DA. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q 1990;68:267-289
3. Rice DP, Fillit HM, Max W, et al. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care 2001;7:809-818
4. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342
5. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002;47:64-70
6. Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273-277
7. Arendt T, Bruckner MK, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development: a study of molecular forms. Neurochem Int 1992;21:381-396
8. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 1979;171:319-327
9. Enz A, Amstutz R, Boddeke H, et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993;98:431-438
10. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998;97:244-250
11. Weinstock M, Razin M, Chorev M, et al. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm Suppl 1994;43:219-225
12. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003;4:131-138
13. Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002;127:6-19
14. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr 2002;14(suppl 1):77-91
15. Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000;15:242-247
16. Exelon [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001
17. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65
18. Anand R, Gharahawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996;8:109-116
19. Anand R, Gharabawi G. Clinical development of Exelon (ENA-713): the ADENA programme. J Drug Dev Clin Pract 1996;8:117-122
20. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145
21. Auriacombe S, Pere JJ, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129-138
22. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994;271:985-991
23. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268
24. Parnetti L, Amici S, Lanari A, et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 2002;23:S95-S96
25. Davidsson P, Blennow K, Andreasen N, et al. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 2001;300:157-160
26. Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003;60:1852-1853
27. Nordberg A, Hellstrom-Lindahl E, Almkvist O, et al. Activity of acetylcholinesterase in CSF increases in Alzheimer's patients after treatment with tacrine. Alzheimers Rep 1999;2:347-352
28. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563-572
29. Nitsch RM, Rossner S, Albrecht C, et al. Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter. J Physiol Paris 1998;92:257-264
30. Aricept [package insert]. New York, NY: Pfizer Inc; 2003
31. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000;57:94-99
32. Rainer M, Mucke HA, Kruger-Rainer C, et al. Cognitive relapse after discontinuation of drag therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. J Neural Transm 2001;108:1327-1333
33. Farlow M, Potkin S, Koumaras B, et al. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003;60:843-848
34. Edwards KR, Goodman W, Khoury KN, et al. Rapid changeover from donepezil to rivastigmine well tolerated [poster]. Presented at the annual meeting of the American Geriatrics Society; May 9-13, 2001; Chicago, Ill. P251:S91-S92
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
36. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
37. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944
38. Galantamine [package insert]. New York, NY: Pfizer Inc; 2003
39. Anand R, Shua-Haim J, Sohn H, et al. Counterintuitive effects of a treatment washout in Alzheimer's disease patients switched from donepezil to rivastigmine [poster]. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; December 11-15, 2000; San Juan, Puerto Rico. Poster session 2
40. Shua-Haim J, Smith JM, Arnin S. Crossover results from donepezil (Aricept) to rivastigmine (Exelon) in Alzheimer's disease patients: an overall analysis of 3 prospective studies [poster]. Presented at the annual meeting of the American Geriatrics Society; May 9-13, 2001; Chicago, Ill. P330:S115
41. Aricept [package insert]. New York, NY: Pfizer Inc; 2004
42. Exelon [package insert]. East Hanover, NJ: Novartis; 2004